Press Releases

Leadership changes at A3P Biomedical

A3P Biomedical (“A3P”) today announces that Chief Executive Officer (“CEO”) David Rosén is leaving his position to pursue other opportunities outside the Group. Executive Chairman Martin Steinberg will lead the company from June 1, with Ola Steinberg as CEO until the appointment of a new CEO.
“The Board extends its gratitude…

Stockholm3 evaluated for Swedish screening program

In 2022, Region Stockholm and Region Gotland (the Region) began a joint three-year project by offering organised prostate cancer testing (OPT) to all 50-year-old men living in the Region. In 2024, an evaluation of the Stockholm3 test will be made in a research project at Karolinska Institutet in collaboration with OPT. On February 12,…

Landmark Stockholm3 North American clinical trial presented at ASCO-GU

The primary results of the landmark SEPTA trial, with over 2,000 racially and ethnically diverse biopsied men recruited in the US and Canada, were presented by Professor Scott Eggener at the ASCO-GU (The American Society of Clinical Oncology – Genitourinary Cancer Symposium) conference in San Francisco on January 26. The study found…

A3P Biomedical and BioAgilytix enter partnership for Stockholm3 in the USA

A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have entered a partnership with the aim of introducing Stockholm3, as a Lab Developed Test (LDT) designed to redefine the standard of care for early detection of prostate cancer in the…

Stockholm3 combines accurate diagnosis of prostate cancer with improved health economics

In a recently published article in Läkartidningen (the Swedish Medical Journal), the Prostate Cancer Center at Capio St. Göran’s Hospital is recognized for its structured and cohesive model (the Capio model) which is based on Stockholm3 and provides significantly improved prostate cancer diagnostics and health economics. The Prostate…

Groves Medical Group starts offering Stockholm3 in the UK

Groves Medical Group has started offering Stockholm3 for prostate cancer testing. This is the first UK clinic that uses Stockholm3.
Stockholm3 will be offered to men aged 45 to 74 in the South-West London area. The blood samples will be taken at the Groves Medical Centre in New Malden, London and the test analysis will be performed by…

A3P Biomedical appoints Andreas Hoel as new VP of Marketing & Sales

A3P Biomedical has appointed Andreas Hoel as VP Marketing & Sales. Andreas Hoel brings more than 20 years´ experience from marketing and sales positions in the life science, diagnostics and medical device industries, most recently at Thermo Fisher in the UK. He joins A3P today and reports to CEO David Rosén.
“I am very pleased…

Zürich University Hospital starts using Stockholm3

Zürich University Hospital has started using Stockholm3 for prostate cancer testing. This is the first clinic in Switzerland that uses Stockholm3.
Stockholm3 will be used for men aged 45 to 75 and offered to men in Switzerland. The blood tests will be taken at the Zürich University Hospital and the test analysis will be performed by…

A3P Biomedical forms Scientific Advisory Board

A3P Biomedical has formed a Scientific Advisory Board (SAB), comprised of scientific and clinical leaders in urology and oncology, and chaired by professor Per-Anders Abrahamsson, former Secretary General of the European Association of Urology (EAU). The SAB will provide expertise and counsel to management in strengthening the clinical…

Stockholm3 in NICE Medtech Innovation Briefing for the UK

NICE, the UK National Institute for Health and Care Excellence, has published a Medtech Innovation Briefing (MIB) on Stockholm3, where experts state that Stockholm3 has the potential of improving accuracy in prostate cancer diagnostics. The MIB report is not a recommendation, but generally seen as a first step towards diagnostic guidance…

Stockholm3 in the Swedish national guidelines for prostate cancer

In February 2022, a proposal for revised Swedish national guidelines for prostate cancer was presented and submitted for consultation. The proposal has now been adopted and the group of experts concluded that there is good evidence that Stockholm3 can select men with PSA above a certain level for further investigation and reduce the…

A3P Biomedical initiates partnership with Unilabs for Stockholm3

A3P Biomedical and Unilabs have initiated a partnership for Stockholm3, A3P Biomedical's blood test for early detection of aggressive prostate cancer. Screening by Stockholm3 is requested by healthcare providers throughout Sweden. The fact that Unilabs now includes Stockholm3 in its catalogue of products will make it possible for…

New Finnish study validates Stockholm3 and shows health economic benefits

At the NUF – Nordisk Urologisk Förening – congress in Helsinki tomorrow a new study that validates the use of Stockholm3 in Finland will be presented. The results of the study show that by using Stockholm3 instead of PSA, the number of men undergoing MRI and/or biopsies could be reduced. The study also shows that the medical…

A3P Biomedical appoints Anders Martin-Löf as new CFO

A3P Biomedical has appointed Anders Martin-Löf as Chief Financial Officer (CFO). Anders Martin-Löf brings more than 20 years’ experience from the life science industry, including CFO positions at Oncopeptides, Wilson Therapeutics and RaySearch Laboratories. He will take up his new position at A3P Biomedical in August and report to…

A3P Biomedical has successfully completed a Private Placement of SEK 400 million

A3P Biomedical AB (publ) (“A3P Biomedical” or the “Company”), a Swedish diagnostic company that specializes in advanced prostate cancer diagnostics, has successfully completed a private placement of shares (the “Private Placement”) of SEK 400 million to Stena Sessan AB, TomEqt Private AB (1), Flerie Invest AB, The Foundation…

Stockholm3 in proposal for new national guidelines in Sweden

On 16 February the revised national prostate cancer guidelines were announced. The revised guidelines state “that there is solid evidence that Stockholm3 can select men with PSA above a certain level for further investigation and, at the same time, reduce the proportion of men who need to undergo magnetic camera examination”. The…

Stockholm3 included in the proposal for new national guidelines in Sweden

On 16 February it was announced that Stockholm3 is included in the revised national prostate cancer guidelines, which have been submitted for consultation and are expected to be introduced in 2022. Stockholm3 is recommended to be included in the projects for organized prostate cancer testing that are planned in Sweden.

Stockholm3 developer Henrik Grönberg named Cancer Researcher of the Year

Professor Henrik Grönberg is awarded the Swedish Cancer Foundation’s Cancer Researcher of the Year 2022 for his research that enables early detection of prostate cancer. Henrik Grönberg’s research has led to the test Stockholm3. The Cancer Foundation’s research committee, chaired by former chairman of the Nobel Committee, Klas…

Fast track publication of the STHLM3 MRI trial in The Lancet Oncology

Stockholm3 in combination with MRI enables implementation of population-based screening of prostate cancer The combination decreases unnecessary biopsies by 74 percent STOCKHOLM, August 13, 2021. A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published…

Stockholm3 abstract wins 1st prize at European Association of Urology

An abstract presenting the STHLM3 MR trial was awarded the “1st Prize Best Abstract Oncology 2021” at the annual European Association of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69 percent compared to…

A3P Biomedical recruits new CEO to lead commercial expansion

STOCKHOLM, June 18, 2021. A3P Biomedical appoints David Rosén as new CEO to lead the commercial expansion of the company’s novel Stockholm3 test for early detection of prostate cancer.  David brings more than 20 years’ experience from the medical device industry, including senior international positions at Getinge and Cantel…

A3P Biomedical strengthens the management team for international expansion

STOCKHOLM, January 10, 2021. A3P Biomedical strengthens the management team with Marianne Waplan as CFO, Marcela Björn as Director of Marketing & Sales and Malin Gidlund as Head of Lab Operations preparing for the company’s international expansion. “In order to realize A3P Biomedical’s growth opportunities, we are building a…

A3P Biomedical raises SEK 110 million in growth capital

A3P Biomedical announced today that it has raised SEK 110 million in growth capital from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test. Near-term, A3P will focus on accelerating the Nordic launch, as well as preparing commercialization in Europe and North…

A3P Biomedical reports strong evidence for Stockholm3 in major Norwegian real-life study

A3P Biomedical announced today that a real-life study including 4,784 men has been carried out by Stavanger University Hospital showing that the company’s blood-based Stockholm3 test leads to a 28 percent reduction in prostate cancer work-up, an increase in identification of clinically significant cancers by 55 percent and reduction of…